Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Occipitoatlantal Dislocation

(2010) Mark Garrett et al.   NEUROSURGERY

Prognostic Significance of Growth Kinetics in Newly Diagnosed Glioblastomas Revealed by Combining Serial Imaging with a Novel Biomathematical Model

(2009) C. H. Wang et al.   CANCER RESEARCH

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

(2009) Philip H. Gutin et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety and Efficacy of Adjunctive Balloon Remodeling during Endovascular Treatment of Intracranial Aneurysms: A Literature Review

(2008) M. Shapiro et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

18F-FDG PET of Common Enhancing Malignant Brain Tumors

(2008) Nobuyuki Kosaka et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Bevacizumab in recurrent malignant glioma

(2008) Lauren E. Abrey   Current Neurology and Neuroscience Reports

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan

(2008) R. M. Zuniga et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab -- News from the Fast Lane?

(2008) M. Weller et al.   NEURO-ONCOLOGY

Experience with irinotecan for the treatment of malignant glioma

(2008) James J. Vredenburgh et al.   NEURO-ONCOLOGY